New research demonstrating the clinical benefits of BLIS M18 has recently been published in the International Journal of Pharma and Bio Science. BLIS M18 is a probiotic that supports oral and periodontal health. The results of this clinical trial, involving 28 adult volunteers, demonstrated statistically significant improvements in multiple indices of periodontal health in the BLIS M18 group following one month of probiotic BLIS M18 lozenge consumption.
 
BLIS M18 is a probiotic member of the bacterial species Streptococcus salivarius originally developed by BLIS Technologies Ltd (Dunedin, New Zealand).  BLIS M18 works through multiple mechanisms to inhibit the growth of bacteria such as Streptococcus mutans, which is involved in the development of dental caries.
 
This trial consisted of 28 volunteers between the ages of 20 to 60 years, displaying varying degrees of poor periodontal health. Volunteers were initially assessed and assigned to active or control groups. Following the initial assessment, each subject underwent professional scaling and root planing. Volunteers in the active group then took two BLIS M18 lozenges (one in the morning and one at night after brushing) daily for 30 days. Clinical parameters were assessed at baseline, day 15, day 30, day 45 and day 60 for all volunteers.
 
Statistically greater dental and periodontal health benefits were observed in the BLIS M18 probiotic group for all parameters at the end of the probiotic intervention period (30 days) when compared to the control group. Interestingly, despite always remaining healthier than the control group, periodontal health gradually declined following cessation of BLIS M18 dosing, demonstrating the need for regular consumption of the probiotic for sustainable health benefits.
 
For more information: www.StratumNutrition.com